Journal of Hematology & Thromboembolic Diseases
Open Access
ISSN: 2329-8790
ISSN: 2329-8790
Dr.Giovanni Brandi
Dr.Giovanni Brandi
Associate Professor of Medical Oncology in the department of Hematology and Oncological Sciences of the Bologna University Medical Shool,
Director of second level Master in Training and Qualification in Palliative Care,
Member of the Board of the Institute of Advanced Studies of the University of Bologna.
Prof. Giovanni Brandi has received Phd in "Biological Markers of tumors of the gastrointestinal tract" in the University of Bologna in 1992. He is currently working as an Associate Professor of Medical Oncology in the department of Hematology and Oncological Sciences of the Bologna University Medical Shool, Director of second level Master in Training and Qualification in Palliative Care, Member of the Board of the Institute of Advanced Studies of the University of Bologna. As a researcher, his research goals are about gastrointestinal tract carcinogenesis, study of the intestinal microbiota and its potential role in the carcinogenesis of gastrointestinal tract and in the toxicity of cancer therapies , treatment of tumors in particular epatobiliopancreatic tumors, neoplasms of the gastrointestinal tract and GIST, primary tumors of the biliary tract and their potential link with asbestos exposure, new treatments for HCC (prolonged intraarterial treatment with irinotecan and metronomic capecitabine) and for pancreatic cancer (use of antiprotease drugs). Based on this research and training in Internal Medicine and Medical Oncology he has received several awards and honors, such as: - for the book " Ultrastructure microbienne Ecologie et du Tube Digestif Humain " G Brandi , AM Flats , G Biasco, awarded in France during the Ninth Edition of the International Scientific Paper (Deauville, Normandy 5 to 7 June 1998) as the best work dedicated to continuing medical education . - PI of the poster : " Occupational exposure to asbestos : a putative unknown risk factors for intrahepatic cholangiocarcinoma " ILCA , Hong Kong , 2011 (ILCA Junior Investigator Award, given to the co-author dr. S. Di Girolamo). He is serving one of the active members of the Global Translational Medicine Consortium (GTMC), that is part of the The European Society for Translational Medicine (EUSTM); AlmaSeq (University of Bologna); Bologna Liver Oncology Group (BLOG); Advisory Board – AstraZeneca (Selumetinibin BiliaryTract Cancer); Clinical Responible for Nanotarget (Barcellona start up of nanotechnology dedicated to the creation of oncology drugs conveyed with nanogold); American Society of Clinical Oncology (ASCO); Member of the “Dyonisos Projet Group" epidemiological research project on liver disease (1991-1996). He has authored more than 80 research articles, 9 books/chapters.
Gastrointestinal tract carcinogenesis, study of the intestinal microbiota and its potential role in the carcinogenesis of gastrointestinal tract and in the toxicity of cancer therapies , treatment of tumors in particular epatobiliopancreatic tumors, neoplasms of the gastrointestinal tract and GIST, primary tumors of the biliary tract and their potential link with asbestos exposure, new treatments for HCC (prolonged intraarterial treatment with irinotecan and metronomic capecitabine) and for pancreatic cancer (use of antiprotease drugs)